Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • Jasper, Alabama • Torrance, California + 8 more

Conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Glenohumeral Osteoarthritis
Interventions: Orthovisc, Control; Device · Drug
Lead sponsor: DePuy Mitek; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 13
States / cities: Encinitas, California • Fresno, California • Coral Gables, Florida + 10 more

Conditions: Pancreatitis, Acute, Alcohol Drinking, Health Behavior
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Osteoarthritis of the Knee
Interventions: Diclofenac Sodium Active Topical Patch 1, Diclofenac Sodium Active Topical Patch 2, Placebo patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Chorioamnionitis
Interventions: Type of glove used for intrapartum vaginal exams; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV-1-infection
Interventions: lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more

Conditions: Diabetic Foot Ulcer
Interventions: Esmolol hydrochloride, Placebo gel; Drug
Lead sponsor: Novalead Pharma Private Limited; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Video Assisted Thoracic Surgery
Interventions: Bupi HCI and lipo bupi, Bupi HCI; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Neuroendocrine Tumors
Interventions: 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution; Drug · Other
Lead sponsor: ITM Solucin GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 6
States / cities: Gilbert, Arizona • Stanford, California • Tampa, Florida + 3 more

Conditions: Drug Abuse
Interventions: Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cigarette Smoking, Nicotine Dependence
Interventions: Counseling Intervention, Information Intervention; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 13 Years to 18 Years
Enrollment: 1,058 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Type 1 Diabetes
Interventions: 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 25
States / cities: La Jolla, California • Palo Alto, California • Sacramento, California + 21 more

Conditions: Cervical Degenerative Disc Disease
Interventions: Anterior Cervical Discectomy and Fusion; Device
Lead sponsor: Synergy Spine Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 23
States / cities: Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 20 more

Conditions: Anemia
Interventions: ferumoxytol or placebo; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 41
States / cities: Mobile, Alabama • Phoenix, Arizona • Mountain View, California + 36 more

Conditions: Alcohol Drinking, Alcohol Intoxication, Alcohol Use, Unspecified
Interventions: WayToServe Plus In-service Component, WayToServe Training Only; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Golden, Colorado

Conditions: Alcohol Drinking, Suicide, Attempted, Adolescent Behavior
Interventions: iASIST; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions: RAD001, MMF; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri

Conditions: Human Papillomavirus
Interventions: Participatory, Efficient; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Renal Transplant Rejection
Interventions: Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Short Bowel Syndrome, Malabsorption, Malnutrition
Interventions: HPN Group Clinic Appointments using Mobile Devices (experimental), Mobile Device Access (placebo); Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 13 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hazardous Behavior, Alcohol Consequences
Interventions: Bystander Brief Motivational Intervention; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 17 Years and older
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

ORTHOVISC Shoulder Osteoarthritis Study

A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis

A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis

Intrapartum Study of Sterile and Clean Gloves

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers

Pectoral Fascial Plane and Serratus Anterior Plane Blocks With Bupivacaine v. Liposomal Bupivacaine

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

School Nurse-Delivered Smoking Cessation Intervention

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery

A Crossover Safety Study of Ferumoxytol Versus Placebo

WayToServePlus: Improving Responsible Alcohol Service Ph II

Brief Alcohol Intervention and mHealth Booster for Suicidal Adolescents

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research

Bystander Intervention for Hazardous Drinking